Increased risk of mycobacterial infections associated with anti-rheumatic medications
Sarah K. Brode(University Health Network), Theodore K. Marras(University of Toronto), Alex Marchand‐Austin(Public Health Ontario), Michael A. Campitelli(Mount Sinai Hospital), J. Michael Paterson(University of Toronto), Claire Bombardier(Toronto General Hospital), Jeffrey C. Kwong(University Health Network), Ryan Ng(Institute for Clinical Evaluative Sciences), Penghui Li, F. Jamieson(Toronto Public Health)
Cited by 172
Related Papers
The american college of rheumatology 1990 criteria for the classification of fibromyalgia
|Arthritis & Rheumatism|1990|9.6k
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
|New England Journal of Medicine|2000|4k
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection
|New England Journal of Medicine|2018|1.2k